NCT Number: NCT05156905
Phase: Phase 1
Trial Summary: The purpose of this study is to examine the safety and efficacy of cirmtuzumab in combination with standard of care docetaxel in patients with metastatic castration resistant prost – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of California, San Diego
Acronym:
Study of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives